Alcohol, Inflammation, and Microbiota in Alcoholic Liver Disease

Area of Science:

• Hepatology
• Gastroenterology
• Immunology

Background:

• Alcoholic liver disease (ALD) is a major health concern linked to excessive alcohol consumption.
• ALD encompasses a spectrum from fatty liver to cirrhosis, driven by alcohol's toxic metabolites and inflammatory responses.
• Intestinal dysbiosis and barrier dysfunction are increasingly recognized as key contributors to ALD progression.

Purpose of the Study:

• To review the role of the intestinal microbiota in alcoholic liver disease.
• To explore therapeutic strategies targeting the gut microbiome for ALD prevention and treatment.

Main Methods:

• Literature review of studies investigating alcohol metabolism, liver inflammation, and gut-liver axis in ALD.
• Analysis of research on the impact of prebiotics, probiotics, postbiotics, and symbiotics on ALD.

Main Results:

• Alcohol metabolism generates reactive oxygen species (ROS) and activates inflammatory pathways involving immune and liver cells.
• Pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) activate Toll-like receptors (TLRs), exacerbating liver inflammation.
• Modulating the intestinal microbiota with prebiotics, probiotics, postbiotics, and symbiotics offers a potential therapeutic avenue for ALD.

Conclusions:

• The gut microbiota plays a critical role in maintaining homeostasis and influences ALD development and progression.
• Targeting intestinal dysbiosis with microbiome-modulating therapies presents a promising strategy for managing alcoholic liver disease.